Q1 Earnings Forecast for KYMR Issued By B. Riley

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at B. Riley issued their Q1 2025 earnings per share estimates for Kymera Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel anticipates that the company will post earnings of ($0.94) per share for the quarter. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($1.09) EPS and Q4 2025 earnings at ($1.09) EPS.

Other analysts also recently issued research reports about the company. BTIG Research started coverage on Kymera Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price objective for the company. UBS Group decreased their target price on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a report on Monday, November 4th. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $38.00 to $57.00 in a report on Monday, December 2nd. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. Finally, BMO Capital Markets began coverage on Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 target price for the company. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $30.17 on Tuesday. Kymera Therapeutics has a fifty-two week low of $29.16 and a fifty-two week high of $53.27. The stock has a 50 day moving average price of $38.81 and a two-hundred day moving average price of $43.66. The company has a market capitalization of $1.95 billion, a P/E ratio of -12.89 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million during the quarter, compared to the consensus estimate of $14.81 million.

Insider Transactions at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company’s stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This represents a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,788 shares of company stock valued at $455,202. Insiders own 15.82% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently modified their holdings of KYMR. Blue Trust Inc. grew its stake in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the last quarter. State of Wyoming purchased a new stake in shares of Kymera Therapeutics during the fourth quarter valued at $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics during the fourth quarter valued at $55,000. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Kymera Therapeutics during the third quarter valued at $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.